Amalgamated Bank lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,696 shares of the medical research company's stock after selling 2,283 shares during the period. Amalgamated Bank's holdings in IQVIA were worth $8,222,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in the business. 1832 Asset Management L.P. increased its stake in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock worth $96,487,000 after purchasing an additional 376,595 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $70,610,000. Impax Asset Management Group plc increased its stake in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after acquiring an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock worth $56,783,000 after buying an additional 198,808 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.
A number of equities analysts recently issued reports on IQV shares. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research report on Tuesday. Robert W. Baird cut their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research report on Monday. Argus upgraded IQVIA to a "strong-buy" rating in a research report on Wednesday, July 31st. Finally, BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $259.13.
View Our Latest Report on IQVIA
Shares of IQV opened at $221.19 on Thursday. IQVIA Holdings Inc. has a 1-year low of $190.20 and a 1-year high of $261.73. The firm's 50 day simple moving average is $232.31 and its 200 day simple moving average is $229.48. The company has a market capitalization of $40.15 billion, a P/E ratio of 29.03, a P/E/G ratio of 2.15 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.